GramEye
Tokyo, Japan· Est.
GramEye develops AI-powered diagnostic tools for early detection and monitoring of eye diseases like glaucoma and diabetic retinopathy.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
GramEye develops AI-powered diagnostic tools for early detection and monitoring of eye diseases like glaucoma and diabetic retinopathy.
Ophthalmology
Technology Platform
AI-powered diagnostic platform using deep learning algorithms to analyze retinal images for detection and monitoring of eye diseases like glaucoma and diabetic retinopathy.
Opportunities
Growing aging population and increasing diabetes prevalence in Japan create strong demand for automated eye disease screening; potential for expansion into adjacent ophthalmic conditions and international markets.
Risk Factors
Regulatory hurdles for AI-based medical devices, competition from established diagnostic companies, and challenges in achieving reimbursement and clinical adoption.
Competitive Landscape
Competes with AI ophthalmology companies like IDx-DR and Eyenuk; differentiation may come from focus on Japanese population data, specific algorithm performance, and integration with local healthcare systems.